Jul 3, 2026 | Acquisition Cost Index (ACI), Benefits preservation, Biosimilar, Client Report, Drug costs, Formularies, MedBen Rx, Rx Costs, Rx Spending, Transparency
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....
May 26, 2026 | Benefits preservation, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
A recent Pharmaceutical Strategies Group analysis shows managing specialty drug costs is now the top priority for employer health plans —surpassing total cost of care. MedBen Rx’s Benefit Preservation Program addresses this by reducing specialty drug spend by an...
May 4, 2026 | Biosimilar, Cost Savings, MedBen Rx, Rx Costs, Rx Spending, Savings
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the...
Mar 23, 2026 | Clinical guidance, Drug costs, MedBen Rx, Rx Advertising, Rx Costs
Heavy direct-to-consumer advertising of high-cost medications is fueling patient demand and placing added pressure on physicians to prescribe the drugs that patients recognize — even when lower-cost alternatives may be just as, or more, effective. The scale of this...
Feb 23, 2026 | Biosimilar, Cost Savings, MedBen Rx, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Jan 12, 2026 | Acquisition Cost Index (ACI), Biosimilar, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance program, Pharmacogenomics, Rx Costs, Rx prices
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
